Knop, S. and Langer, C. and Engelhardt, M. and Stuebig, T. and Schreder, M. and Dechow, T. and Muegge, L. -O. and Bassermann, F. and Schaefer-Eckart, K. and Blau, I. -W. and Wolleschak, D. and Kropff, M. and Reichle, A. and von Metzler, I. and Metzner, B. and Roellig, C. and Hertenstein, B. and Pfreundschuh, M. and Duerk, H. and Biersack, H. and Ostermann, H. and Menzel, H. and Schleicher, J. and Gramatzki, M. and Gerecke, C. and Mueller, M. and Brueggemann, M. and Held, S. and Einsele, H.
(2017)
Lenalidomide, adriamycin and dexamethasone (RAD) versus bortezomib, lenalidomide and dexamethasone (VRD) as induction regimens in newly diagnosed multiple myeloma - first results from the DSMM XIV study.
ONCOLOGY RESEARCH AND TREATMENT, 40 (Suppl3).
p. 36.
ISSN 2296-5270, 2296-5262
Full text not available from this repository.
Actions (login required)
 |
View Item |
